Financing of Chinese IVD Companies

Ustar Completed a Financing of Several Hundred Million Yuan

CACLP2021: N3-T029 

Recently, Ustar Biotechnologies (Hangzhou) Ltd., an enterprise in the molecular POCT industry, completed a new round of financing of several hundred million yuan, led by Oriental Fortune Capital, followed by CD Capital, JG Investment and Juxie Capital. The financing is mainly used for the research and development, registration of new products and the expansion of the existing production line. Banyan Capital serves as the exclusive financial adviser for this round of financing.

GENFINE BIOTECH announced the Completion of A round of Financing of 150 Million Yuan

CACLP2021: N4-S050

GENFINE BIOTECH(BEIJING)CO.,LTD. recently announced the completion of A round of financing of 150 million yuan. This round of financing was jointly led by Legend Capital and Sequoia Capital China Fund. The raised funds will mainly be used to promote the research and development of the company's sample pre-processing products, related channel construction and overseas market expansion.

Accunome Announced the Completion of a Round of A2 Financing of Nearly 100 Million Yuan

On February 10, 2021, Accunome announced the completion of a round of A2 financing of nearly 100 million yuan, which was invested by Sinovation Ventures. The financing will mainly be used for clinical trials of instruments and reagents products, NMPA license applications and product conversion.

Led by Sinocare, Legendaibiochip Announced the Completion of  Pre-A Round of Financing of 35 Million Yuan

Sinocare in CACLP2021: N8-T024 

On February 1, 2021, "legendaibiochip", a development enterprise of biological chip and testing platform, announced the completion of  pre-A round of financing of 35 million yuan. This round of financing was led by Sinocare, followed by Lucky Source Funds, and North Beta Capital acted as the financial adviser for this transaction. The funds will be used to build a manufacturing facility and develop new products, as well as promote the marketing of the company's chemiluminescence biochips, instruments and procalcitonin chemiluminescence kits.

Vision Medicals Completed a C Round of Financing of RMB 200 Million

On February 4, 2021, Guangzhou Vision Medicals Technology Co., Ltd., an affiliated company of Vision Medicals, completed a C round of financing of RMB 200 million. This round of financing was led by Tencent Investment, with CICC Capital, CDH Investments and other existing shareholders participating in the investment. This is a new round of financing within half a year after Vision Medicals completed its B round of financing of 200 million yuan in August 2020. This round of financing will continue to focus on product development and upgrading, medical device product registration, strengthening medical brand marketing and clinical services and other strategic directions.